Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API


EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, will present at two upcoming virtual conferences:


GlobeNewswire Inc | Nov 11, 2021 07:00AM EST

November 11, 2021

WATERTOWN, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, will present at two upcoming virtual conferences:

-- Jefferies London Healthcare ConferenceForum: Corporate PresentationDate: Thursday, November 18, 2021Time: 3:00 a.m. ET

-- 33rd Annual Piper Sandler Virtual Healthcare ConferenceForum: Corporate PresentationDate: Monday, November 22nd, 2021Time: 10:00 a.m. ET

A webcast and subsequent archived replay of each corporate presentation may be accessed via the Investors section of the Company website atwww.eyepointpharma.com. The Jefferies presentation replay will be available for 30 days after the event, and the Piper Sandler presentation will be available for 90 days after the event.

About EyePoint Pharmaceuticals, Inc.(Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert technology for sustained intraocular drug delivery including EYP-1901, a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The Company has two commercial products: YUTIQ, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, for the treatment of postoperative inflammation following ocular surgery.EyePoint Pharmaceuticalsis headquartered in Watertown, Massachusetts. To learn more about the Company, please visitwww.eyepointpharma.comand connect on Twitter and LinkedIn.

Investors:

Christina TartagliaStern IRDirect: 212-698-8700christina.tartaglia@sternir.com

Media Contact

Amy PhillipsGreen Room CommunicationsDirect: 412-327-9499aphillips@greenroompr.com







Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC